跳至主要内容
临床试验/EUCTR2011-000571-13-DK
EUCTR2011-000571-13-DK进行中(未招募)不适用

The effect of GLP-1 in psoriasis

Gentofte Hospital0 个研究点开始时间: 2011年4月26日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Caucasians above 18 years of age
  • Plaque psoriasis
  • PASI score >10
  • No treatment or stable treatment of psoriasis during at least 3 months before inclusion
  • Steady weight through 3 months with a body mass index (BMI) of maximum 30kg/m2
  • Normal blood pressure
  • Spiral or hormonal birth control
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Psoriasis arthritis
  • Fasting plasma glucose > 7.5 mmol/L
  • Type 1 diabetes
  • Type 2 diabetes
  • Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or GLP-1-receptor-agonists)
  • Heart failure, NYHA class III-IV
  • Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine >150 µM and/or albuminuria
  • Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) >2 x upper normal serum levels)
  • Screening calcitonin >50ng/L
  • Acute or chronic pancreatitis
  • Struma or thyroid cancer
  • Pregnancy or breast feeding
  • Inability to complete the study

研究者

相似试验

The effect of GLP-1 (glucagon-like peptide-1) in... | 临床试验